Document is current

Article History

Received: 26 August 2025

Accepted: 20 October 2025

First Online: 25 November 2025

Declarations

:

: I. Rizzello has received honoraria from Amgen, GlaxoSmithKline and Sanofi and advisory role for GlaxoSmithKline and Menarini Stemline. A. Belotti has participated in Advisory Board for Amgen, GlaxoSmithKline, Pfizer, Sanofi, Menarini Stemline, Janssen. N. Sgherza has served in advisory boards for Sanofi. R. Zambello has served in advisory boards for Amgen, Janssen, Sanofi, GlaxoSmithKline, Oncopeptides, Menarini, Pfizer. G. Barilà has served on Advisory Board for Menarini Stemline, Sanofi, Pfizer and has received honoraria from Sanofi, Johnson and Johnson, Menarini Stemline, Amgen, BMS. K. Mancuso has received honoraria from Celgene, Takeda, Amgen, Sanofi and Janssen. L. Pantani has received honoraria from GlaxoSmithKline, Pfizer and Sanofi. P. Tacchetti has received honoraria from Amgen, Bristol-Myers Squibb/Celgene, Janssen, Takeda, AbbVie, Sanofi, GlaxoSmithKline, and Pfizer. M. Cavo has received honoraria and has served in a consulting/advisory role for Amgen, AbbVie, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Menarini Stemline, Sanofi, and Karyopharm Therapeutics. E. Zamagni has received honoraria and has served in advisory role for Janssen, Bristol-Myers Squibb, Sanofi, Amgen, GlaxoSmithKline, Pfizer, Oncopeptides, Menarini Stemline. I. Sacchetti, S. Barbato, V. Solli, P. Stefanoni, L. Cani, M. Quaresima, M. Gentile, M. Celli, G. Mele, M. Talarico, M. Puppi, E. Manzato, R. Restuccia, S. Masci, S. Ghibellini, and F. Bigi declare no potential conflicts of interest.

: The study was approved by CE-AVEC and by local Ethics Committee in each participating center. The study was conducted in accordance with the International Conference on Harmonization Guidelines on Good Clinical Practice and the principles of the Declaration of Helsinki. All participants signed an informed consent form prior to their inclusion in the study.